Establishing an Institute for Ultimate Oncology Science Research in Abu Dhabi

The Department of Health – Abu Dhabi, the organizational authority for the health care sector in the emirate, and the Abu Dhabi Investment Office, signed a memorandum of understanding with the Glaxo Smith Clean, a pioneer in the field of biological medicines, to cooperate for the establishment of an Institute for the Multix Science Research in Abu Dhabi, on the sidelines of the activities of Abu Dhabi International Health Week, and this cooperation seeks to accelerate the pace of developing genome science and careful medicine that focuses on Tumors, as well as enhance diversity and global representation in genome research with the aim of improving the therapeutic results of cancer patients.

Multimsement omeglams are a methodology of research aimed at studying multiple types of biological molecules such as genes, ribosia DNA, proteins, and volatile to understand their complex interactions in living organisms, where researchers can integrate data from these specialties to form a more comprehensive understanding of biological processes and various causes of health and disease.

The Undersecretary of the Health Department – Abu Dhabi, Dr. Noura Khamis Al -Ghaithi, stressed that the establishment of the Institute of Multix Science Research reflects the emirate’s commitment to enhancing its research capabilities and employing advanced technologies in the service of careful medicine, and said: “In line with our vision to develop one of the most intelligent health care systems around the world, we continue to invest in scientific research and technology to advance the prospects of careful medicine and develop innovative treatments that meet the needs of different societies Around the world. There is no doubt that the new institute will contribute to the production of specific data that supports efforts to develop innovative health care solutions, and establish the position of Abu Dhabi as an advanced center for life sciences, and embodies our commitment to expanding the prospects for international cooperation in the areas of prevention and the efforts of new treatments for tumors.

This initiative will benefit from the advanced infrastructure in the fields of biotechnology and genome science in Abu Dhabi to integrate discovery research in the early stages within the scientific research system in the UAE for the first time, which will enhance the pace of innovation in oncology, and supports the diversity of genomic research, which contributes to improving the treatment results of cancer patients in the long run.

In turn, the Director General of the Abu Dhabi Investment Office, Badr Salim Sultan Al -Ulama, said: “The launch of the Institute for Oncology Research is a pivotal step that reflects the established status of Abu Dhabi as a global destination for innovation in the health sector. Through the adoption of an integrated research approach that combines oncology sciences and exact vital specialties, we contribute to supporting advanced research to treat cancer, and at the same time enhance the leadership of the emirate in areas Exact medicine, biotechnology, and health innovation. Based on our commitment to scientific distinction and the consolidation of multidisciplinary partnerships, we trust that this cooperation will open new horizons to transform scientific research into influential and sustainable solutions, contributing to the future of health care in Abu Dhabi and the world.

For his part, Dr. Hisham Abdullah, First Vice President and Head of the Oncology, Research and Development Department at Glaxo Smith Klein, stressed the importance of this cooperation, noting that this is a note that represents a major step towards achieving common aspirations to employ advanced scientific capabilities in the Middle East to generate multi -omex science data that supports applied research and speeds up the pace of discovering new treatments for tumors. He said: “Cooperation between the public and private sectors is a fundamental factor to enhance our understanding of disease biology, and to achieve tangible progress in treating cancer at the level of the UAE and the world.”

The signing and Mansour Ibrahim Al -Mansoori, Head of the Health Department – Abu Dhabi, Ahmed Jassim Al -Zaabi, Head of the Department of Economic Development – Abu Dhabi, Sir Jonathan Simmonds, Chairman of the Board of Directors of Glaxo Smith Klein, Boub Boub Boubi Chonghavis, Vice President and Director General of Glaxo Smith Clean Gulf, was witnessed. Badr Salim Sultan Al -Ulama, Director General of the Abu Dhabi Investment Office, and Hisham Abdullah, First Vice President and Head of the International Oncology, Research and Development Department at Glaxo Smith Klein.